Responses
. | High-dose IFN; n = 201 . | Low-dose IFN; n = 206 . |
|---|---|---|
| Hematologic response at 6 mo, n (%) | ||
| Evaluable patients | 170 | 170 |
| Complete response | 121 (71) | 128 (75) |
| Partial response | 35 (21) | 28 (16) |
| Failure | 12 (7) | 12 (7) |
| Dead from disease at 6 mo | 2 (1) | 2 (1) |
| Nonevaluable patients | 31 | 36 |
| Dead from cause unrelated to disease at 6 mo | 3 | 3 |
| Missing data | 28 | 33 |
| Best cytogenetic response, n (%) | ||
| Evaluable patients | 173 | 181 |
| Complete response (0% Ph+) | 12 (7) | 17 (9) |
| Partial response (1%-35% Ph+) | 23 (13) | 27 (15) |
| Minimal response (36%-95% Ph+) | 49 (28) | 53 (29) |
| No response | 70 (40) | 73 (40) |
| Early progression/death | 13 (8) | 8 (4) |
| Early side effects | 6 (3) | 3 (2) |
| Nonevaluable patients | 28 | 25 |
| Not tested | 25* | 23 |
| Early transplantation | 1 | 2 |
| IFN abandoned early or never started | 2 | 0 |
. | High-dose IFN; n = 201 . | Low-dose IFN; n = 206 . |
|---|---|---|
| Hematologic response at 6 mo, n (%) | ||
| Evaluable patients | 170 | 170 |
| Complete response | 121 (71) | 128 (75) |
| Partial response | 35 (21) | 28 (16) |
| Failure | 12 (7) | 12 (7) |
| Dead from disease at 6 mo | 2 (1) | 2 (1) |
| Nonevaluable patients | 31 | 36 |
| Dead from cause unrelated to disease at 6 mo | 3 | 3 |
| Missing data | 28 | 33 |
| Best cytogenetic response, n (%) | ||
| Evaluable patients | 173 | 181 |
| Complete response (0% Ph+) | 12 (7) | 17 (9) |
| Partial response (1%-35% Ph+) | 23 (13) | 27 (15) |
| Minimal response (36%-95% Ph+) | 49 (28) | 53 (29) |
| No response | 70 (40) | 73 (40) |
| Early progression/death | 13 (8) | 8 (4) |
| Early side effects | 6 (3) | 3 (2) |
| Nonevaluable patients | 28 | 25 |
| Not tested | 25* | 23 |
| Early transplantation | 1 | 2 |
| IFN abandoned early or never started | 2 | 0 |
Includes 1 patient with a dry tap.